Molecular credentialing of rodent bladder carcinogenesis models

Neoplasia

Volumn 10, Issue 8, 2008, Pages 838-846

  Williams, Paul D ^a   Lee, Jae K ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; N N BUTYL N (4 HYDROXYBUTYL) NITROSAMINE; NITROSAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; UROGENITAL TRACT CANCER;

EID: 48249133328     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08432     Document Type: Article

References (38)

1. American Cancer Society (2008). Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society.
2. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al. (2001). Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19, 666-675.
3. Howe GR, Burch JD, Miller AB, Cook GM, Esteve J, Morrison B, Gordon P, Chambers LW, Fodor G, and Winsor GM (1980). Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst 64, 701-713.
4. Wynder EL and Goldsmith R (1977). The epidemiology of bladder cancer: a second look. Cancer 40, 1246-1268.
5. Cole P, Hoover R, and Friedell GH (1972). Occupation and cancer of the lower urinary tract. Cancer 29, 1250-1260.
6. Matanoski GM and Elliott EA (1981). Bladder cancer epidemiology. Epidemiol Rev 3, 203-229.
7. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, and Seibert K (2000). Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60, 5599-5602.
8. Grubbs CJ, Moon RC, Squire RA, Farrow GM, Stinson SF, Goodman DG, Brown CC, and Sporn MB (1977). 13-cis-Retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl) nitrosamine. Science 198, 743-744.
9. Druckrey H, Preussmann R, Ivankovic S, Schmidt CH, Mennel HD, and Stahl KW (1964). Selective induction of bladder cancer in rats by dibutyl- and N-butyl-N-butanol(4)-nitrosamine. Z Krebsforsch 66, 280-290.
10. Fukushima S, Hirose M, Tsuda H, Shirai T, and Hirao K (1976). Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gann 67, 81-90.
11. Kunze E, Schauer A, and Schatt S (1976). Stages of transformation in the development of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced transitional cell carcinomas in the urinary bladder of rats. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 87, 139-160.
12. Yao R, Lemon WJ, Wang Y, Grubbs CJ, Lubet RA, and You M (2004). Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl) nitrosamine. Neoplasia 6, 569-577.
13. Yao R, Yi Y, Grubbs CJ, Lubet RA, and You M (2007). Gene expression profiling of chemically induced rat bladder tumors. Neoplasia 9, 207-221.
14. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, and Edgar R (2007). NCBI GEO: mining tens of millions of expression profiles - database and tools update. Nucleic Acids Res 35, D760-D765.
15. Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K, and ∅rntoft TF (2004). Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64, 4040-4048.
16. Edgar R, Domrachev M, and Lash AE (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30, 207-210.
17. Smith SC, Oxford G, Baras AS, Owens C, Havaleshko D, Brautigan DL, Safo MK, and Theodorescu D (2007). Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin Cancer Res 13, 3803-3813.
18. Bolstad BM, Irizarry RA, Astrand M, and Speed TP (2003). A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193.
19. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, and Speed TP (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31, e15.
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, and Speed TP (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264.
21. Liu G, Loraine AE, Shigeta R, Cline M, Cheng J, Valmeekam V, Sun S, Kulp D, and Siani-Rose MA (2003). NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res 31, 82-86.
22. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al. (2003). PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34, 267-273.
23. Subramanian A, Kuehn H, Gould J, Tamayo P, and Mesirov JP (2007). GSEAP: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 23, 3251-3253.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545-15550.
25. Wu Z, Siadaty MS, Riddick G, Frierson HF Jr, Lee JK, Golden W, Knuutila S, Hampton GM, El-Rifai W, and Theodorescu D (2006). A novel method for gene expression mapping of metastatic competence in human bladder cancer. Neoplasia 8, 181-189.
26. Lam SH, Wu YL, Vega VB, Miller LD, Spitsbergen J, Tong Y, Zhan H, Govindarajan KR, Lee S, Mathavan S, et al. (2006). Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol 24, 73-75.
27. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, and Thorgeirsson SS (2004). Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36, 1306-1311.
28. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, and Jacks T (2005). An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37, 48-55.
29. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, et al. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8, R76.
30. 1. Mol Cell 2, 163-171.
31. Labbe JC, Capony JP, Caput D, Cavadore JC, Derancourt J, Kaghad M, Lelias JM, Picard A, and Doree M (1989). MPF from starfish oocytes at first meiotic metaphase is a heterodimer containing one molecule of cdc2 and one molecule of cyclin B. EMBO J 8, 3053-3058.
32. Nurse P and Bissett Y (1981). Gene required in G1 for commitment to cell cycle and in G2 for control of mitosis in fission yeast. Nature 292, 558-560.
33. Nurse P and Thuriaux P (1980). Regulatory genes controlling mitosis in the fission yeast Schizosaccharomyces pombe. Genetics 96, 627-637.
34. Li Y and Benezra R (1996). Identification of a human mitotic checkpoint gene: hsMAD2. Science 274, 246-248.
35. Pagano M, Pepperkok R, Verde F, Ansorge W, and Draetta G (1992). Cyclin A is required at two points in the human cell cycle. EMBO J 11, 961-971.
36. Kalaydjieva L, Gresham D, Gooding R, Heather L, Baas F, de Jonge R, Blechschmidt K, Angelicheva D, Chandler D, Worsley P, et al. (2000). N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet 67, 47-58.
37. Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, Mansson W, Fioretos T, and Hoglund M (2006). Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 25, 2685-2696.
38. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, et al. (2005). Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11, 4044-4055.